Latest Safety News

Page 6 of 252
xReality Group expanded its Operator XR customer base, recurring revenue and sales pipeline in the first quarter, while securing its first US Marine Corps order after quarter end. But the company remains focused on completing its FY26 audit and reinstating trading, with $1.4 million in quarter-end cash against $4.55 million of secured debt.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Aurora Labs has moved another step from propulsion development toward commercial production, securing AS9100D certification and its first US engine order while customer enquiries expand. But with only A$1.148 million in cash at quarter-end and 1.5 quarters of funding estimated, the A$6 million raise is central to the next phase.
Victor Sage
Victor Sage
30 Oct 2026
Environmental Clean Technologies has produced its first MXene on a US Flash Joule Heating reactor, marking a technical step in its defence materials strategy. The harder work now is proving repeatability, performance and customer qualification while building a separate PFAS pilot.
Victor Sage
Victor Sage
30 Oct 2026
Hydrix reported September-quarter revenue growth of 11.6% year on year and secured further medical and Defence milestones. But with $1.5 million in cash and reported funding covering only 1.30 quarters, the company still needs contract wins to convert into receipts and revenue.
Sophie Babbage
Sophie Babbage
29 Oct 2026
Spacetalk’s active Mobile subscriber base rose 20% to 61.4k in the September quarter, but revenue fell 32% to $3.1 million as device sales, App revenue and Schools income declined. The $10 million placement lifted cash to $5.2 million, although the company reported only 1.4 quarters of funding at its current operating cash burn.
Victor Sage
Victor Sage
29 Oct 2026
Chimeric Therapeutics has stopped enrolment and dosing in its CHM-2101 CAR-T trial after a safety review found the highest dose unsafe. With $1.35 million in cash, suspended securities and uncertain creditor negotiations, the company is now pursuing a possible recapitalisation while preserving a preclinical CDH17 pathway.
Ada Torres
Ada Torres
29 Oct 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
HyTerra Limited (ASX: HYT) will not proceed with a second McCoy-1 test for now after the Kansas well produced only about 0.1 Mscf/d of gas, with air-corrected hydrogen of 0.4%. The company is reassessing the Ridge Play while shifting attention to its larger Rift Play and preserving cash.
Maxwell Dee
Maxwell Dee
29 Oct 2026
D3 Energy has expanded its South African acreage and secured Strategic Integrated Project status after drilling two gas-bearing wells at Nooitgedacht. A 5.2% helium sample is encouraging, but production testing, methane retesting and funding remain unresolved.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Bannerman Energy has cleared the two gates that mattered most for Etango: funding and Final Investment Decision. The Namibia uranium project now enters full-scale construction, with first production targeted for 2028 and construction cash largely in place.
Maxwell Dee
Maxwell Dee
29 Oct 2026
8common remained EBITDA and operating-cashflow positive in the September quarter, even as revenue fell 7.8% year on year. Its $1.9 million Australian Taxation Office contract is yet to contribute revenue, with implementation expected to begin in January.
Victor Sage
Victor Sage
29 Oct 2026
Noxopharm has halted trading in its securities while it prepares an announcement about a capital raising. The suspension is scheduled to last until the earlier of the announcement or the start of trading on 2 November 2026, unless ASX decides otherwise.
Ada Torres
Ada Torres
29 Oct 2026

Browse the archive

Full archive